DOCSLIB.ORG

Atopiclair Roundtable Supplement Saved Version.Qxd 11/12/08 10:59 AM Page C1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Atopiclair Roundtable Supplement Saved Version.Qxd 11/12/08 10:59 AM Page C1 Atopiclair_Roundtable_Supplement_Saved_Version.qxd 11/12/08 10:59 AM Page C1 Supplement B to the November issue of MAS063DP (Atopiclair ®) for the Treatment of Atopic Dermatitis in Infants and Children: Proceedings of a Roundtable Discussion Atopiclair_Roundtable_Supplement_Saved_Version.qxd 11/12/08 10:59 AM Page C2 Participants A Message from the Moderator: Adelaide A. Hebert, MD Eric W. Baum, MD, MSc The science of atopic der- Director of Medical Education matitis has come a long way in the Alabama Dermatology Society last few years. While today, der- Gadsden, Alabama matologists are using the term Dr. James Del Rosso, DO, FAOCD barrier dysfunction, it was not Dermatology Residency Director something that specialists dis- Valley Hospital Medical Center Clinical Associate Professor cussed two or three years ago, (Dermatology) even though it was known that University of Nevada School of Medicine, Las Vegas, Nevada there was a barrier defect that Associate Professor (Dermatology) required ongoing management. A Touro University College of Osteopathic Medicine growing need for nonsteroidal Henderson, Nevada therapy for atopic dermatitis exists, especially for infants and chil- dren. Nonsteroidal barrier repair is currently being intensely re- searched. An important recent study involves a nonsteroidal, barrier repair cream by the name of Atopiclair® (Graceway Pharmaceuticals, LLC, Bristol, Tennessee). The following clinical review discusses a multi- center, randomized, placebo-controlled study evaluating the efficacy and safety of Atopiclair in infants and children with mild-to-moderate Gregory A. Dwyer, MD atopic dermatitis. The study demonstrated that Atopiclair cream is Little Rock Dermatology Clinic effective and safe as a monotherapy for the treatment of symptoms Little Rock, Arkansas of mild-to-moderate atopic dermatitis in infants and children. Mark Boguniewicz, MD, of the National Jewish Medical and Research Center in Denver, Colorado, was the lead investigator for this impor- tant pediatric study.1 Adelaide A. Hebert, MD, is Professor of Dermatology and Pediatrics at the University of Texas—Houston Medical School, in Joseph S. Eastern, MD Houston, Texas. Dr. Hebert is board certified in dermatology, pedi- Belleville Dermatology Center Belleville, New Jersey atric dermatology, and wound healing. Her medical training includes a fellowship in pediatric dermatology at Northwestern University. She joined the dermatology faculty of UT Houston in 1986. This supplement is based on a roundtable discussion that took place on June 28, 2008, at the Sandestin Beach Hilton Hotel in Mark D. Herron, MD Sandestin, Florida. Dr. Hebert moderated the discussion. Clinical Instructor Roundtable participants included Drs. Baum, Del Rosso, Dwyer, Department of Dermatology University of Alabama at Birmingham Eastern, and Herron. This supplement was supported by Graceway Birmingham, Alabama Pharmaceuticals and did not undergo peer review by The Journal of Clinical and Aesthetic Dermatology’s Editorial Advisory Board. Atopiclair_Roundtable_Supplement_Saved_Version.qxd 11/12/08 10:59 AM Page 3 MAS063DP (Atopiclair®) for the Treatment of Atopic Dermatitis in Infants and Children Proceedings of a Roundtable Discussion Introduction On June 28, 2008, a roundtable discussion was held to endpoints included IGA at other time points, patient’s/care- review the management of atopic dermatitis in pediatric giver’s assessment of pruritus, onset, duration of itch relief, patients. This roundtable took place during the Alabama Eczema Area and Severity Index (EASI), subject’s/caregiver’s Dermatological Society meeting in San Destin, Florida. Dr. assessment of global response, and need for rescue med- Adelaide Hebert, Professor of Dermatology and Pediatrics ication (such as a topical corticosteroid) in the event of an at the University of Texas Houston Medical School— atopic dermatitis flare. Atopiclair cream was statistically Houston, Texas, served as chair and moderator of the ses- more effective (P<0.0001) than vehicle cream for the pri- sion. A primary objective of the session was to discuss mary endpoint and all secondary endpoints and proved to recently published data on the use of a nonsteroidal topical be safe and well tolerated. The results of this pediatric study barrier repair cream that contains glycyrrhetinic acid 2%, were compared to those reported in a previous study com- hyaluronic acid, Vitis Vinifera extract (grapevine), pleted in adult subjects. telmesteine, and Butyrospermum parkii (shea butter), and The roundtable discussion was not limited to the is marketed under the trade name Atopiclair (Graceway results of the pediatric trial summarized above. Other Pharmaceuticals, LLC, Bristol, Tennessee). issues that were addressed included management of epi- A multicenter, randomized, vehicle-controlled study dermal barrier dysfunction, trigger factors for atopic der- recently published in the June 2008 issue of the Journal of matitis, superimposed bacterial infections, and associ- Pediatrics evaluated the use of Atopiclair as monotherapy ated behavioral and emotional sequelae of the disease. In for mild-to-moderate atopic dermatitis in infants and chil- addition to Dr. Hebert, who served as chair and modera- dren. This multicenter, randomized, placebo-controlled, 43- tor, other roundtable discussion participants included Eric day study included 142 subjects. Mark Boguniewicz, MD, of W. Baum, MD; Joseph S. Eastern, MD; Gregory A. Dwyer, the National Jewish Medical and Research Center in Denver, MD; and Mark D. Herron, MD. Colorado, served as lead investigator. Atopic dermatitis was We are hopeful that the information presented in this assessed to cover at least five-percent body surface area for roundtable proceedings will be helpful to you in clinical all patients at study entry, with evaluations occurring at practice. baseline and Days 3, 8, 15, 22, 29, and 43. The primary endpoint of this pediatric study was Investigator Global James Q. Del Rosso, DO, Editor-in-Chief, Clinical Dermatology, Assessment (IGA) of atopic dermatitis at Day 22. Secondary The Journal of Clinical and Aesthetic Dermatology [NOVEMBER 2008 • VOLUME 1 • NUMBER 4] SUPPLEMENT B TO THE JOURNAL OF CLINICAL AND AESTHETIC DERMATOLOGY 3 Atopiclair_Roundtable_Supplement_Saved_Version.qxd 11/12/08 10:59 AM Page 4 Atopiclair is Effective Monotherapy for Mild to Moderate Atopic Dermatitis in Infants and Children: A Multicenter, Randomized, Vehicle-controlled Study Boguniewicz M, Zeichner JA, Eichenfield LF, et al. MAS063DP is effective monotherapy for mild to moderate atopic dermatitis in infants and children: a multicenter, randomized, vehicle-controlled study. J Pediatr. 2008;152(6):854-859. Study Highlights Objective. To examine the efficacy and safety of Atopiclair cream in the management of mild-to-moderate dermatitis in infants and children. Study design. One-hundred forty-two patients aged six months to 12 years were administered Atopiclair (n=72) or vehicle (n=70) cream three times per day to affected areas and sites prone to develop atopic dermatitis. The primary endpoint for efficacy was the Investigator’s Global Assessment at Day 22. Secondary endpoints included IGA at other time points, patient’s/caregiver’s assessment of pruritus, onset, duration of itch relief, Eczema Area and Severity Index (EASI), subject’s/caregiver’s assessment of global response, and need for rescue medication (such as a topical corticosteroid) in the event of an atopic dermatitis flare. Results. Atopiclair cream was statistically more effective (P<0.0001) than vehicle cream for the primary endpoint and all secondary endpoints. Treatment discontinuation as a result of an adverse event occurred in 9.9 percent of patients using Atopiclair cream and 16 percent of patients using vehicle cream. Conclusion. Atopiclair cream is effective and safe as monotherapy for the treatment of symptoms of mild-to-moderate atopic dermatitis in infants and children. 4 SUPPLEMENT B TO THE JOURNAL OF CLINICAL AND AESTHETIC DERMATOLOGY [NOVEMBER 2008 • VOLUME 1 • NUMBER 4] Atopiclair_Roundtable_Supplement_Saved_Version.qxd 11/12/08 10:59 AM Page 5 MAS063DP (Atopiclair®) for the Treatment of Atopic Dermatitis in Infants and Children: Proceedings of a Roundtable Discussion Roundtable Discussion Atopiclair has antioxidant and antiprotease activity, which helps protect against breakdown of the epider- mis.4 Telmestine has antiprotease action and inhibits What was the objective of the recently elastase, collagenase, and matrix metalloproteinase, published Atopiclair pediatric trial? which are expressed at high levels in patients with atopic dermatitis.5 Atopic dermatitis has a complex etiology that encom- Finally, hyaluronic acid in the emollient helps to passes many genetic as well as environmental triggers hydrate the epidermis and restore barrier function. that compromise skin-barrier function. As a result of our The hyaluronic acid component is a naturally occur- understanding of the pathophysiology of atopic dermatitis ring glycosaminoglycan and is part of the ground sub- increasing in recent years, newer therapeutic options such stance of connective tissue, which immediately as Atopiclair have become available that may significantly smoothes skin upon application and, as a naturally improve quality of life for infants and children with atopic occurring substance, creates no immunogenic dermatitis. The objective of the pediatric trial was to response.6 The hyaluronic acid component may play a examine the efficacy and
Load more

Recommended publications
  • BODY LOTIONS/CREAMS and HOMOEOPATHY © Dr
    BODY LOTIONS/CREAMS AND HOMOEOPATHY © Dr. Rajneesh Kumar Sharma M.D. (Homoeopathy) Homoeo Cure & Research Centre P. Ltd. NH 74, Moradabad Road, Kashipur (Uttaranchal) INDIA, Pin- 244713 Ph. 05947- 260327, 9897618594 [email protected], [email protected] Definition There are two types of body lotions and creams- 1- Moisturizers, lubricants or softening ones. 2- Cleansing ones. 1- Body lotions and creams are the cosmetic emollient substances, which when applied to skin, protect it from loss of moisture, lubricating and softening dead keratin, thereby lowering the rate at which water evaporates from the skin surface, acting similarly to the natural sebum, secreted by sebaceous glands of the skin. 2- Cleansing creams and lotions are detergent-based or emulsified oil systems that are designed primarily for the removal of surface oil, pollutants, or cellular debris along with makeup. History Perfumed oils About 3100–2907 BC, during the First empire of Egypt, men and women used perfumed oils, stored in unguent jars made of alabaster and marble, to maintain soft, supple, and unwrinkled skin. Face pack By the middle of the first century AD, Romans used a face pack of barley-bean flour, egg, and mashed narcissus bulbs to promote smooth skin. Cold cream A Greek physician of the second century AD invented cold cream containing water, beeswax, and olive oil. When rubbed on the face, the water evaporated, cooling the skin. (Cold cream formulations of the 1920s were of similar composition.) Oiled packs By 1700, smooth skin was in fashion and women applied oiled cloths on their foreheads and wore gloves in bed to prevent wrinkles.
    [Show full text]
  • EL 04-85-GC1 a Study to Define a Set of Requirements for Cleansing Agents for Use in the Space Station Whole Body Shower
    FINAL REPORT NAS 9-17428 - EL 04-85-GC1 A Study To Define A Set of Requirements For Cleansing Agents For Use in the Space Station Whole Body Shower. October 29, 1985 _ , MT.X \t> )> C ^ ^>'- N86-16903 S final Unclas 05 ml HC A05/WF A01 ECONOMICS LABORATORY. INC. Osborn Building St. Paul, Minnesota 55102 INDEX CONTENTS PAGE Introduction Final Report 1-26 Table #1 - Foam Test Results Table #2 - Shampoo Ingredient Comparisons Appendix A - Database References Appendix B - Dermal Sensitization Study Appendix C - Eye Irritation Study Appendix D - Protocol For Comparing Shampoos Appendix E - Detergent Filming Build Up Study Figure 1 - Whole Body Portable Shower Head Unit Page 2 October 25, 1985 NAS 9-17428 - EL 04-85-GC1 INTRODUCTION The purpose of this contract is to assist NASA engineers in defining a set of requirements for a whole body cleansing agent to be used in the Space Station Whole Body Shower System. In addition, cleansing agent candidates are to be identified that are likely to satisfy requirements defined in the first part of the study. It is understood that the main reason for having a Whole Body Shower is to satisfy the physiological, psychological and social needs of the crew throughout the duration of duty in ^ the Space Station. The cleansing agent must also be compatible with the vortex water/gas separator and the water reclamation system. To accomplish these goals the study was divided into six tasks. These tasks are as follows: 1. Task One: Survey literature and unpublished information to ascertain state-of-the-art in Whole Body Shower cleansing and the potential impacts of extended use of WBS cleansing agents in a mic'rogravity environment.
    [Show full text]
  • Dermatological Conditions
    18 Dermatological Conditions JAMES E. LESSENGER Key words: predisposing factors, patch testing, wood’s light, urticarian, dermatitis Skin problems in worldwide agricultural workers are very common. Among California grape and tomato harvesters, pustular eruptions such as acne and fol- liculitis were present in 30% of studied workers. Irritant or allergic contact der- matitis was present in 2%. In Iowa, 9.6% of male farmers and 14.4% of wives of farmers reported dermatitis during the previous 12-month period. In Washington State, researchers studied 7445 claims for occupational skin disorders filed over a 5-year period. Medical bills totaled $1.22 million, and lost time payments were $1.23 million. The highest rates of occupational skin disorder claims were seen in agriculture with 2.8 claims per 10,000 full-time equivalent employee years. Most of these skin disorders were due to chemical and vegetation exposures (1–4). Among northern Ecuadorian potato farm workers, high rates of dermatitis and pigmentation disorders were attributable to the use of pesticides and fungi- cides. Among California farm workers, skin disease rates were found in tomato workers (6.2%), citrus (10.8%), and vineyard workers (21.0%). Factors found to contribute to dermatitis in farm workers included the specific type of crop cul- tivated, specific job activity, use of personal protective measures, field and home sanitation, environmental conditions of heat and humidity, personal hygiene, allergic history (including atopy), and ethnicity. Several pesticides were shown to cause irritant and allergic contact dermatitis. Causes were found to include pes- ticides, naturally occurring plant substances, heat, sunlight and humidity, atopy, and infectious fungal and bacterial agents (5,6).
    [Show full text]
  • 15 Occupational Irritant Dermatitis – Metal Workers
    137 15 Occupational Irritant Dermatitis – Metal Workers Undine Berndt, Peter Elsner Contents tates the skin by denaturating keratin, defatting and dehydrating the stratum corneum [6, 7]. In addition, References . 138 frequent wetting and drying cycles contribute to the skin-damaging effect. An above-average incidence of irritant contact dermatitis in those machinists who work at machines with short running periods and do Although computerized tooling operations are in- mechanical work in between has been observed [8]. creasing, the metalworking industry is a trade that Within the phase of manual work, the cutting fluid continues to have a great deal of work done by hand. that the workers are exposed to during machine oper- Consequently, the parts of the body which are pre- ating dries on the skin surface, thus reaching a higher, dominantly affected by occupational skin disease are and thus, irritant concentration. the hands and forearms. Among the frequently ob- served cases of hand dermatitis in metalworkers, the vast majority is of irritant origin [1, 2] (Fig. 1). This condition is closely related to exposure to metalwork- ing fluids. These liquids are sprayed or flow over the Number of case work piece that is being shaped by different mechani- cal means, such as turning, drilling, grinding, or plan- ing. Thus, cutting fluids carry away the produced heat and decrease its production by lubricating the area Observation period (years) between the tool and the metal so as to minimize fric- Fig. 1. Cumulative incidence of irritant hand dermatitis dur- tion. Secondly, they wash away metal chips, reduce ing the observation of 201 trainee metal workers over a period strain hardening, and protect the workpiece against of 2.5 years [9] rusting [3,4].
    [Show full text]
  • Skin Notation (SK) Profile Pentachlorophenol (PCP) [CAS No
    Skin Notation (SK) Profile Pentachlorophenol (PCP) [CAS No. 87-86-5] Department of Health and Human Services Centers for Disease Control and Prevention National Institute for Occupational Safety and Health Disclaimer Mention of any company or product does not constitute endorsement by the National Institute for Occupational Safety and Health (NIOSH). In addition, citations to Web sites external to NIOSH do not constitute NIOSH endorsement of the sponsoring organizations or their programs or products. Furthermore, NIOSH is not responsible for the content of these Web sites. Ordering Information To receive this document or information about other occupational safety and health topics, contact NIOSH: Telephone: 1-800-CDC-INFO (1-800-232-4636) TTY: 1-888-232-6348 E-mail: [email protected] Or visit the NIOSH Web site: www.cdc.gov/niosh For a monthly update on news at NIOSH, subscribe to NIOSH eNews by visiting www.cdc.gov/niosh/eNews. Suggested Citation NIOSH [20XX]. NIOSH skin notation profile: Pentachlorophenol (PCP). By Hudson NL, Dotson GS. Cincinnati, OH: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. XXX DHHS (NIOSH) Publication No. XXX ii This information is distributed solely for the purpose of pre-dissemination peer review under applicable information quality guidelines. It has not been formally disseminated by the National Institute for Occupational Safety and Health. It does not represent and should not be construed to represent any agency determination or policy. Foreword As the largest organ of the body, the skin performs multiple critical functions, such as serving as the primary barrier to the external environment.
    [Show full text]
  • Journal of the Society of Cosmetic Chemists 1976 Volume.27 No.3
    Voi. 27 No. 3 March 1976 Journal of the Society of Cosmetic Chemists■ C o n te n ts Page REVIEW PAPER The nature of dandruff Albert M. Kligman, Kenneth J. McGinley, and James J. Leyden ................................................................................ Ill ORIGINAL PAPER Neue insektenabwehrmittel-am Stickstoff disubstituierte /3-alaninderivate (New insect repellent derivatives of N-diubstituted /3-alanine) Manfred Klier and Friedrich Kuhlow ........ ..................................... 141 DEPARTMENTS Synposes fo r c a rd in d e x e s ......................................................................................... XIX In d e x to a d v e rtis e r s ...................................................................................................... XXI Ü* jb. ' ' ' M JJ** La Gronda Sphinx, Asia Minor, 4th Century B.C What sets man apart from all other forms of life is creativity. And it is creativity that sets Givaudan apart. QVAUDAN ïttdeSÉeiïceiif* « < # creativity Givaudan Corporation, 100 Delawanna Avenue,Clifton, N.J.07014. In Canada Givaudan Limited. 60 Overlea Boulevard. Toronto. Ontario Also Argentina • Australia • Brazil • Columbia • England • France • West Germany • Hong Kong • Italy • Japan • Mexico • Republic of South For cold wave lotions and depilatories use Evans Thioglycol made from uniform and high quality vacuum di THIOGLYCOLIC ACID. EVANS THIOGLYCOLATES can help you three important advantages for your cold perman wave and depilatory formulations: (1) uniformity, (2) purity, (3) high quality. Get additional information from EVANS technical service specialists in the field of hair chemistry. EVANS SPECIALIZES IN COMPOUNDS FOR COLD WAVE LOTIONS (PERMS) Emulsifier K-700— a lanolin clouding agent with four ounces of water will produce a for PERMS containing wetting agents and viscous on-the-rod neutralizer. conditioning oils. 4. High Speed Neutralizer containing sodium PERM Neutralizers perborate monohydrate as the active in­ gredient is available either in foil enve­ 1.
    [Show full text]
  • Environmental Health Criteria 242
    INTERNATIONAL PROGRAMME ON CHEMICAL SAFETY Environmental Health Criteria 242 DERMAL EXPOSURE IOMC INTER-ORGANIZATION PROGRAMME FOR THE SOUND MANAGEMENT OF CHEMICALS A cooperative agreement among FAO, ILO, UNDP, UNEP, UNIDO, UNITAR, WHO, World Bank and OECD This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization The International Programme on Chemical Safety (IPCS) was established in 1980. The overall objec- tives of the IPCS are to establish the scientific basis for assessment of the risk to human health and the environment from exposure to chemicals, through international peer review processes, as a prerequi- site for the promotion of chemical safety, and to provide technical assistance in strengthening national capacities for the sound management of chemicals. This publication was developed in the IOMC context. The contents do not necessarily reflect the views or stated policies of individual IOMC Participating Organizations. The Inter-Organization Programme for the Sound Management of Chemicals (IOMC) was established in 1995 following recommendations made by the 1992 UN Conference on Environment and Development to strengthen cooperation and increase international coordination in the field of chemical safety. The Participating Organizations are: FAO, ILO, UNDP, UNEP, UNIDO, UNITAR, WHO, World Bank and OECD. The purpose of the IOMC is to promote coordination of the policies and activities pursued by the Participating Organizations, jointly or separately, to achieve the sound management of chemicals in relation to human health and the environment. WHO Library Cataloguing-in-Publication Data Dermal exposure. (Environmental health criteria ; 242) 1.Hazardous Substances - poisoning.
    [Show full text]
  • 21 Atopic Dermatitis (Atopic Eczema, Disseminated Neurodermatitis, Besnier’S Prurigo)
    21 Atopic Dermatitis (Atopic Eczema, Disseminated Neurodermatitis, Besnier’s Prurigo) INTRODUCTION Atopic dermatitis is the cutaneous component of a complex hereditary predisposition that also includes a tendency toward bronchial asthma and immediate type I allergy to a range of environmental antigens manifest by allergic conjunctivitis. The linkage among the three is poorly understood but with careful history taking, 75 to 80% of patients are found to have a positive family history. Atopic dermatitis is a multifaceted problem and exhibits diverse physiological defects, which continue to lead investigators in many different directions. Among the more prominent features, there is evidence of a functioning, but disordered, immune system that overreacts through humoral mechanisms to common environmental antigens (pollen, danders, foods, house dust), while responses of the delayed or cellular immune system to certain antigens (toxicodendron, candida, tuberculin, and some viruses) are depressed. This defect of immune modulation is clinically manifest by abnormal handling of certain otherwise minor infections. Other features include inherently dry skin, altered vasomotor responses, and disturbed sweating with sweat retention. It is beyond the scope of this book to discuss the complex interactions in atopic der- matitis, but the practitioner must be aware of their existence, as they can be important in the recognition and treatment of certain cases. CLINICAL APPLICATION QUESTIONS A 68-year-old retired bank executive seeks your help regarding a progressively dis- abling and intensely pruritic rash that has generalized over the past 6 months. Examination reveals a widespread inflammatory dermatitis with excoriations and impetiginization. Heavily involved areas include the face, neck, upper back, scalp, and the dorsum of the hands.
    [Show full text]
  • Atopic Dermatitis (1 of 13)
    Atopic Dermatitis (1 of 13) 1 Patient presents w/ skin manifestations suggestive of atopic dermatitis 2 DIAGNOSIS No ALTERNATIVE Do history & physical exam DIAGNOSIS confirm atopic dermatitis? Yes Patient suff ers from acute fl are-up Patient suff ers from disease of pruritus & inflammation persistence or frequent recurrences ACUTE FLAREUP TREATMENT MAINTENANCE TREATMENT A Non-pharmacological therapy A Non-pharmacological therapy • Patient/caregiver education • Same as acute fl are-up • Avoidance of trigger factors • Investigate precipitating factors of each fl are-up • Skin care • Phototherapy* - Bathing B Pharmacological therapy - Moisturizers/emollients Start at earliest sign of local recurrence: - Wet dressing • Calcineurin inhibitor (topical) B Pharmacological therapy or Any one of the following agents: Long-term: • Corticosteroid (topical) • Calcineurin inhibitor (topical), combined w/ • Calcineurin inhibitor (topical) • Corticosteroids (topical), intermittent use If skin infection is present: If skin infection is present: • Appropriate antibiotics, antifungals, • Antibiotics, antifungals, antivirals (oral &/or topical) antivirals (oral &/or topical) Symptomatic relief of pruritus: Symptomatic relief of pruritus: • Antihistamine (oral) • Antihistamine (oral) MIMS • • Continue Expert referral is recommended • non- Psychotherapeutic/ pharmacological psychopharmacological options therapy may be combined w/ the therapies EVALUATION listed below • Discontinue Yes No Disease A topical Non-pharmacological therapy remission (Severe • Continue therapy above corticosteroid &/ Refractory • Phototherapy or calcineurin Atopic B inhibitor Dermatitis) Pharmacological therapy • Potent corticosteroids (topical) © • Systemic corticosteroids • Systemic immunosuppressants *May be considered in patients >6 years of age w/ Scoring of Atopic Dermatitis (SCORAD) score of 25-50. Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS.
    [Show full text]
  • Atopic Dermatitis: a Practice Parameter Update 2012
    Practice parameter Atopic dermatitis: A practice parameter update 2012 Authors: Lynda Schneider, MD, Stephen Tilles, MD, Peter Lio, MD, Mark Boguniewicz, MD, Lisa Beck, MD, Jennifer LeBovidge, PhD, and Natalija Novak, MD Joint Task Force Contributors: David Bernstein, MD, Joann Blessing-Moore, MD, David Khan, MD, David Lang, MD, Richard Nicklas, MD, John Oppenheimer, MD, Jay Portnoy, MD, Christopher Randolph, MD, Diane Schuller, MD, Sheldon Spector, MD, Stephen Tilles, MD, and Dana Wallace, MD This parameter was developed by the Joint Task Force on Practice Parameters for Allergy & Immunology are available Practice Parameters, representing the American Academy of online at http://www.jcaai.org. (J Allergy Clin Immunol Allergy, Asthma & Immunology (AAAAI); the American 2013;131:295-9.) College of Allergy, Asthma & Immunology (ACAAI); and the Key words: Joint Council of Allergy, Asthma and Immunology. The AAAAI Atopic dermatitis/atopic eczema, pathogenesis, genet- and the ACAAI have jointly accepted responsibility for ics, diagnosis, management, therapy, triggers, Staphylococcus, qual- establishing ‘‘Atopic dermatitis: a practice parameter update ity of life, sleep, cyclosporine, immunomodulating agents, 2012.’’ This is a complete and comprehensive document at phototherapy, allergen immunotherapy the current time. The medical environment is a changing environment, and not all recommendations will be appropriate To read the Practice Parameter in its entirety, please download for all patients. Because this document incorporated the the online version of this article from www.jacionline.org. Please efforts of many participants, no single individual, including note that all references cited in this print version can be found in those who served on the Joint Task Force, is authorized to the full online document.
    [Show full text]
  • Allergen Preparation and Standardization: an Update
    Global Journal of Otolaryngology ISSN 2474-7556 Review Article Glob J Otolaryngol Volume 17 Issue 4 - September 2018 DOI: 10.19080/GJO.2018.17.555968 Copyright © All rights are reserved by AB Singh Allergen Preparation and Standardization: An Update AB Singh* Ex-Emeritus Scientist, CSIR-Institute of Genomics & Integrative Biology, India Submission: September 03, 2018; Published: September 11, 2018 *Corresponding author: AB Singh, Ex-Emeritus Scientist, CSIR-Institute of Genomics & Integrative Biology, India, Tel: 91-9811554462, Email: Abstract Allergy is defined as an exaggerated response of the adaptive immune system typified by immunoglobulin E (IgE) responses against the angioedema,offending substance allergic called rhinoconjunctivitis, ‘allergen’ [1]. The allergic immunologic asthma, serumbasis of sickness, allergic diseasesallergic vasculitis, is observed hypersensitivity in two phases: pneumonitis,sensitization andatopic development dermatitis of memory T and B cell responses along with IgE production [2]. Allergy manifests in form of various conditions such as anaphylaxis, urticaria, (eczema), contact dermatitis and granulomatous reactions, as well as the colorful spectrum of food or drug - induced hypersensitivity reactions to[2]. 4 Asthma,billion in allergic 2050s rhinitis,[5]. atopic dermatitis and inhalant sensitization have been appropriately referred to as first wave of the epidemic of the 21st century [3,4]. During the last 60 years, there has been a rise in the epidemic prevalence of allergic disorders, which is expected to reach up Allergic reactions are initiated by certain types of antigens, referred to as allergens, which have been broadly categorized into four classes as Inhalant (pollen,fungi,dust), Ingestants (food, drugs), Contactants (latex, plant trichomes) and Injectants (drugs).
    [Show full text]
  • Format (Sample) Dissertation
    Development and Evaluation of a Clinical Practice Guideline to Promote Evidence-Based Treatment of Childhood Atopic Dermatitis in Primary Care Item Type text; Electronic Dissertation Authors Zook, Tiffany Anne Crawford Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 28/09/2021 00:29:28 Link to Item http://hdl.handle.net/10150/621743 DEVELOPMENT AND EVALUATION OF A CLINICAL PRACTICE GUIDELINE TO PROMOTE EVIDENCE-BASED TREATMENT OF CHILDHOOD ATOPIC DERMATITIS IN PRIMARY CARE by Tiffany Anne Crawford Zook ________________________ Copyright © Tiffany Anne Crawford Zook 2016 A DNP Project Submitted to the Faculty of the COLLEGE OF NURSING In Partial Fulfillment of the Requirements For the Degree of DOCTOR OF NURSING PRACTICE In the Graduate College THE UNIVERSITY OF ARIZONA 2 0 1 6 2 THE UNIVERSITY OF ARIZONA GRADUATE COLLEGE As members of the DNP Project Committee, we certify that we have read the DNP Project prepared by Tiffany Anne Crawford Zook entitled Development and Evaluation of a Clinical Practice Guideline to Promote Evidence-Based Treatment of Childhood Atopic Dermatitis in Primary Care and recommend that it be accepted as fulfilling the DNP Project requirement for the Degree of Doctor of Nursing Practice. _______________________________________________ Date: July 28, 2016 Gloanna Peek, PhD, RN, CPNP _______________________________________________ Date: July 28, 2016 Lorri Marie Phipps, DNP, RN, CPNP _______________________________________________ Date: July 28, 2016 Luz Wiley, DNP, RN, APRN-BC Final approval and acceptance of this DNP Project is contingent upon the candidate’s submission of the final copies of the DNP Project to the Graduate College.
    [Show full text]